These findings contradict the reported poor prognosis of breast, colorectal, pancreatic, ovarian and bladder cancers over-expressing EpCAM48–56, but is in line with the association of high levels of EpCAM with improved prognosis of colonic, gastric and renal cancer57–59. This evidence concerns the gene EPCAM and urinary bladder cancer.